Document is current
Any future updates will be listed below
-
Authors
Sims, Zachary
Mills, Gordon B. https://orcid.org/0000-0002-0144-9614
Chang, Young Hwan https://orcid.org/0000-0001-8764-1959
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA253860)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U2CCA233280)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U2CCA233280)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 5 September 2023
Accepted: 26 March 2024
First Online: 3 April 2024
Competing interests
: The authors declare the following competing interests: G.B.M. is a SAB member or Consultant: for Amphista, Astex, AstraZeneca, BlueDot, Chrysallis Biotechnology, Ellipses Pharma, GSK, ImmunoMET, Infinity, Ionis, Leapfrog Bio, Lilly, Medacorp, Nanostring, Nuvectis, PDX Pharmaceuticals, Qureator, Roche, Signalchem Lifesciences, Tarveda, Turbine, Zentalis Pharmaceuticals. G.B.M. has Stock/Options/Financial relationships with: Bluedot, Catena Pharmaceuticals, ImmunoMet, Nuvectis, SignalChem, Tarveda, and Turbine. G.B.M. has Licensed Technology: HRD assay to Myriad Genetics, DSP patents with Nanostring. G.B.M. has Sponsored research with AstraZeneca. The other authors declare no competing interests.
